Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Accumulated Expenses: 2011-2017

Historic Other Accumulated Expenses for Vanda Pharmaceuticals (VNDA) over the last 7 years, with Dec 2017 value amounting to $2.0 million.

  • Vanda Pharmaceuticals' Other Accumulated Expenses rose 8.93% to $2.0 million in Q1 2018 from the same period last year, while for Mar 2018 it was $2.0 million, marking a year-over-year increase of 8.93%. This contributed to the annual value of $2.0 million for FY2017, which is 75.84% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $2.0 million for FY2017, which was up 75.84% from $1.1 million recorded in FY2016.
  • Vanda Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $2.0 million for FY2014, and its period low was $665,000 during FY2013.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $1.7 million (2015), whereas its average is $1.6 million.
  • In the last 5 years, Vanda Pharmaceuticals' Other Accumulated Expenses skyrocketed by 203.76% in 2014 and then crashed by 32.66% in 2016.
  • Over the past 5 years, Vanda Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $665,000 in 2013, then spiked by 203.76% to $2.0 million in 2014, then declined by 16.63% to $1.7 million in 2015, then tumbled by 32.66% to $1.1 million in 2016, then surged by 75.84% to $2.0 million in 2017.